Sarepta Therapeutics/$SRPT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Sarepta Therapeutics
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Ticker
$SRPT
Sector
Primary listing
Employees
1,372
Headquarters
Website
SRPT Metrics
BasicAdvanced
$2B
-
-$2.77
0.52
-
Price and volume
Market cap
$2B
Beta
0.52
52-week high
$133.15
52-week low
$10.42
Average daily volume
6.3M
Financial strength
Current ratio
2.954
Quick ratio
1.353
Long term debt to equity
94.703
Total debt to equity
95.473
Interest coverage (TTM)
-4.68%
Profitability
EBITDA (TTM)
-43.032
Gross margin (TTM)
18.39%
Net profit margin (TTM)
-11.25%
Operating margin (TTM)
-3.56%
Effective tax rate (TTM)
-7.66%
Revenue per employee (TTM)
$1,760,000
Management effectiveness
Return on assets (TTM)
-1.52%
Return on equity (TTM)
-21.37%
Valuation
Price to revenue (TTM)
0.758
Price to book
1.48
Price to tangible book (TTM)
1.48
Growth
Revenue change (TTM)
47.15%
Earnings per share change (TTM)
-327.17%
3-year revenue growth (CAGR)
40.19%
10-year revenue growth (CAGR)
212.70%
3-year earnings per share growth (CAGR)
-30.41%
10-year earnings per share growth (CAGR)
-5.40%
What the Analysts think about SRPT
Analyst ratings (Buy, Hold, Sell) for Sarepta Therapeutics stock.
Bulls say / Bears say
Sarepta has resumed U.S. shipments of its Elevidys gene therapy for patients able to walk after the FDA lifted its voluntary hold, lifting shares 36% in premarket trade. (Reuters)
The company reported second-quarter 2025 revenue of $611.1 million, a 68% increase from a year earlier, driven by broader Elevidys label approval and a milestone payment from Roche. (Sarepta Investor Relations)
In the third quarter, Sarepta posted an adjusted loss of $0.13 per share, beating analyst forecasts of a $0.32 loss and showing stronger-than-expected control of costs. (Barron's)
The European Medicines Agency declined to recommend approval of Elevidys for Duchenne muscular dystrophy, causing Sarepta shares to fall nearly 13% and delaying potential expansion into the EU market. (Reuters)
The U.S. Food and Drug Administration asked Sarepta to voluntarily stop all U.S. shipments of Elevidys gene therapy after two teenage patients died, resulting in a nearly 35% drop in the stock. (Reuters)
A confirmatory trial for the approved DMD therapies casimersen and golodirsen failed to reach its main efficacy goal, leading Sarepta's share price to drop about 36%. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2025.
SRPT Financial Performance
Revenues and expenses
SRPT Earnings Performance
Company profitability
SRPT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sarepta Therapeutics stock?
Sarepta Therapeutics (SRPT) has a market cap of $2B as of November 06, 2025.
What is the P/E ratio for Sarepta Therapeutics stock?
The price to earnings (P/E) ratio for Sarepta Therapeutics (SRPT) stock is 0 as of November 06, 2025.
Does Sarepta Therapeutics stock pay dividends?
No, Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders as of November 06, 2025.
When is the next Sarepta Therapeutics dividend payment date?
Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders.
What is the beta indicator for Sarepta Therapeutics?
Sarepta Therapeutics (SRPT) has a beta rating of 0.52. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.